RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer

Translational Oncology

Volumn 4, Issue 4, 2011, Pages 212-221

  Ehlén, Åsa ^a   Nodin, Björn ^a   Rexhepaj, Elton ^b   Brändstedt, Jenny ^a   Uhlén, Mathias ^c   Alvarado Kristensson, Maria ^a   Pontén, Fredrik ^d   Brennan, Donal J ^b   Jirström, Karin ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; DNA; MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN 3; RNA BINDING MOTIF PROTEIN 3; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; DNA DAMAGE; EPITHELIAL OVARIAN CANCER; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

EID: 79960336702     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11106     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
2. Guarneri V, Piacentini F, Barbieri E, and Conte PF (2010). Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 117, 152-158.
3. Hennessy BT, Coleman RL, and Markman M (2009). Ovarian cancer. Lancet 374, 1371-1382.
4. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, and Gallagher WM (2010). Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 10, 605-617.
5. Burd CG and Dreyfuss G (1994). Conserved structures and diversity of functions of RNA-binding proteins. Science 265, 615-621.
6. Sutherland LC, Rintala-Maki ND, White RD, and Morin CD (2005). RNA binding motif (RBM) proteins: a novel family of apoptosis modulators? J Cell Biochem 94, 5-24.
7. Wright CF, Oswald BW, and Dellis S (2001). Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins. J Biol Chem 276, 40680-40686.
8. Bjorling E, Lindskog C, Oksvold P, Linne J, Kampf C, Hober S, Uhlen M, and Ponten F (2008). A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 7, 825-844.
9. Ponten F, Jirstrom K, and Uhlen M (2008). The Human Protein Atlas-a tool for pathology. J Pathol 216, 387-393.
10. Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S, Uhlen M, Landberg G, Pahlman S, et al. (2009). Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol 22, 1564-1574.
11. Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al. (2010). Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 8, 78.
12. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14, 5198-5208.
13. Bolstad BM, Irizarry RA, Astrand M, and Speed TP (2003). A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193.
14. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, and Chodosh LA (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197-209.
15. Andersson AC, Stromberg S, Backvall H, Kampf C, Uhlen M, Wester K, and Ponten F (2006). Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics. J Histochem Cytochem 54, 1413-1423.
16. Uhlen M and Ponten F (2005). Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 4, 384-393.
17. Team RDC (2008). A language and environment for statistical computing. R Foundation for Statistical Computing.
18. Gautier L, Cope L, Bolstad BM, and Irizarry RA (2004). Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315.
19. Smyth G (2005). Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor, 397-420.
20. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. (2003). PGC-1α- responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267-273.
21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545-15550.
22. Lofstedt T, Jogi A, Sigvardsson M, Gradin K, Poellinger L, Pahlman S, and Axelson H (2004). Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 279, 39223-39231.
23. Wellmann S, Buhrer C, Moderegger E, Zelmer A, Kirschner R, Koehne P, Fujita J, and Seeger K (2004). Oxygen-regulated expression of the RNA-binding proteins RBM3and CIRP by a HIF-1-independent mechanism. J Cell Sci 117, 1785-1794.
24. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847.
25. Bartek J and Lukas J (2007). DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 19, 238-245.
26. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374.
27. Kastan MB and Bartek J (2004). Cell-cycle checkpoints and cancer. Nature 432, 316-323.
28. Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, et al. (2008). Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 27, 4544-4556.
29. Lundgren K, Holm K, Nordenskjold B, Borg A, and Landberg G (2008). Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res 10, R81.
30. Narod SA (2010). Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin Genet 78, 1-7.
31. Kaneko YS, Watanabe N, Morisaki H, Akita H, Fujimoto A, Tominaga K, Terasawa M, Tachibana A, Ikeda K, and Nakanishi M (1999). Cell-cycle- dependent and ATM-independent expression of human Chk1 kinase. Oncogene 18, 3673-3681.
32. Matsuoka S, Huang M, and Elledge SJ (1998). Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-1897.
33. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, and Elledge SJ (1997).Conservation of theChk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501.
34. Shieh SY, Ahn J, Tamai K, Taya Y, and Prives C (2000). The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14, 289-300.
35. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, and Helleday T (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7, 195-201.
36. Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, and Azorsa DO (2010). RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol 118, 220-227.
37. Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, and Damia G (2008). Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res 14, 5131-5141.
38. Paparatto D, Fletcher D, Piwowar K, Baldino K, Morel C, and Dunaway S (2009). The Schizosaccharomyces pombe checkpoint kinases Chk1 and Cds1 are important for cell survival in response to cisplatin. PLoS One 4, e6181.
39. Sorensen CS, Syljuasen RG, Lukas J, and Bartek J (2004). ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage. Cell Cycle 3, 941-945.
40. Bucher N and Britten CD (2008). G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 98, 523-528.
41. Bailis JM and Forsburg SL (2004). MCM proteins: DNA damage, mutagenesis and repair. Curr Opin Genet Dev 14, 17-21.
42. Lei M (2005). The MCM complex: its role in DNA replication and implications for cancer therapy. Curr Cancer Drug Targets 5, 365-380.
43. Soling A, Sackewitz M, Volkmar M, Schaarschmidt D, Jacob R, Holzhausen HJ, and Rainov NG (2005). Minichromosome maintenance protein 3 elicits a cancerrestricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res 11, 249-258.
44. Lau KM, Chan QK, Pang JC, Li KK, Yeung WW, Chung NY, Lui PC, Tam YS, Li HM, Zhou L, et al. (2010). Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion. Oncogene 29, 5475-5489.
45. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, et al. (2006). Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98, 472-482.
46. Derry JM, Kerns JA, and Francke U (1995). RBM3, a novel human gene in Xp11.23 with a putative RNA-binding domain. Hum Mol Genet 4, 2307-2311.
47. Dresios J, Aschrafi A, Owens GC, Vanderklish PW, Edelman GM, and Mauro VP (2005). Cold stress-induced protein Rbm3 binds 60S ribosomal subunits, alters microRNA levels, and enhances global protein synthesis. Proc Natl Acad Sci USA 102, 1865-1870.
48. Smart F, Aschrafi A, Atkins A, Owens GC, Pilotte J, Cunningham BA, and Vanderklish PW (2007). Two isoforms of the cold-inducible mRNA-binding protein RBM3 localize to dendrites and promote translation. J Neurochem 101, 1367-1379.
49. Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, and Buhrer C (2010). The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res 67, 35-41.
50. Bartek J, Bartkova J, and Lukas J (2007). DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773-7779.
51. Halazonetis TD, Gorgoulis VG, and Bartek J (2008). An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355.